Squarepoint
UTHR icon

Squarepoint’s United Therapeutics UTHR Stock Holding History

Squarepoint’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.08M Buy
5,200
+4,400
+550% +$2.19M ﹤0.01% 1873
2025
Q4 		$390K Buy
800
+200
+33% +$93.1K ﹤0.01% 3411
2025
Q3 		$252K Buy
+600
New +$202K ﹤0.01% 3797
2025
Q2 		– Sell
-1,400
Closed -$432K – 5095
2025
Q1 		$432K Sell
1,400
-1,000
-42% -$343K ﹤0.01% 3440
2024
Q4 		$847K Sell
2,400
-5,300
-69% -$1.95M ﹤0.01% 3220
2024
Q3 		$2.76M Sell
7,700
-5,200
-40% -$1.76M ﹤0.01% 1841
2024
Q2 		$4.11M Buy
+12,900
New +$3.41M 0.01% 1506
2022
Q4 		– Sell
-1,300
Closed -$272K – 3627
2022
Q3 		$272K Buy
1,300
+100
+8% +$22.4K ﹤0.01% 2538
2022
Q2 		$283K Buy
+1,200
New +$244K ﹤0.01% 2314

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Squarepoint's UTHR Position: Q4 2025 in Review

Squarepoint sold out of United Therapeutics (UTHR) in Q4 2025, closing a stake of 31,296 shares — an estimated $14.6M sold.

Squarepoint first reported a position in UTHR in Q4 2015 and held it in 32 quarters. The position peaked at $40.8M in Q1 2024. 837 funds tracked by Wall St. Rank hold UTHR as of Q4 2025.

  • Squarepoint reported no remaining United Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Squarepoint sold 31,296 United Therapeutics shares in Q4 2025, an estimated $14.6M.
  • Squarepoint first reported a position in United Therapeutics in Q4 2015 and held it in 32 quarters.
  • Squarepoint's United Therapeutics position peaked at $40.8M in Q1 2024.
  • 837 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2025.

Based on Squarepoint's 13F filing for Q4 2025, filed 13 Feb 2026.